利拉鲁肽注射液与胰岛素联合用于治疗老年肥胖糖尿病的疗效及安全性分析

Efficacy and Safety of Liraglutide Injection Combined with Insulin in the Treatment of Obese Diabetic Patients

目的观察分析对老年肥胖糖尿病患者在临床中行利拉鲁肽注射液与胰岛素进行联合治疗的效果。方法择取在2016年8月—2018年7月时段到该院就诊的86例老年肥胖糖尿病患者,将随机数字表法作为分组法则,均分为参照组(n=43)、研究组(n=43),参照组病患接受胰岛素、二甲双胍联合治疗;研究组病患接受胰岛素、利拉鲁肽注射液联合治疗,统计治疗前后血糖指标(空腹血糖、餐后2h血糖、糖化血红蛋白)改善情况、BMI指数、体质量、每日胰岛素剂量情况、不良反应发生情况、血糖变异指标(全天血糖标准差、日间血糖平均绝对差、最大血糖波动幅度)指标情况,并进行评价与对比分析。结果①研究组、参照组不良反应发生率分别为9.32%、23.26%,经对比差异有统计学意义(χ^2=7.125,P=0.008)。②治疗前,对比两组FPG等多项血糖指标水平、BMI等情况(P>0.05);治疗后研究组FPG为(6.04±1.50)mmol/L、2hPG为(6.42±1.18)mmol/L、HbAlc为(7.01±1.40)%显著优于参照组(t=5.823、7.240、4.957,P=0.000、0.000、0.000)。③研究组SD、CV-FPG、MODD分别为(0.85±0.26)mmol/L、(0.16±0.03)、(0.65±0.25)mmol/L,对照组分别为(1.43±0.37)mmol/L、(0.24±0.05)、(1.39±0.39)mmol/L,经对比差异用统计学意义(t=8.410、8.997、10.475,P=0.000、0.000、0.000)。结论在临床中对于老年肥胖糖尿病而言,对其应用胰岛素、利拉鲁肽注射液进行联合治疗,可有效控制血糖指标水平,于血糖便易指标波动而言,具有降低的功效,还能够改善体质量等,且具有较高的安全性,应当进一步推广与应用。

Objective To observe the effect of combined treatment with liraglutide injection and insulin in elderly patients with obese diabetes.Methods 86 elderly patients with obese diabetes who were admitted to our hospital from August 2016 to July 2018 were enrolled.The random number table method was used as the grouping rule,which was divided into reference group(n=43)and study group(n=43),the reference group received insulin and metformin combination therapy;the study group received insulin and liraglutide injection combined treatment,statistical improvement of blood glucose indicators(fasting blood glucose,postprandial 2 h blood glucose,glycosylated hemoglobin)before and after treatment,BMI index,body mass,daily insulin dose,adverse reaction occurrence,blood glucose variability index(full-day blood glucose standard deviation,average daily blood glucose absolute difference,maximum blood glucose fluctuation amplitude)indicators,and evaluation and comparative analysis were implemented.Results 1.The incidence of adverse reactions in the study group and the reference group were 9.32%and 23.26%,respectively.The difference was statistically significant(χ^2=7.125,P=0.008).2.Before treatment,compare the blood glucose levels and BMI of the two groups(P>0.05);after treatment,the FPG of the study group was(6.04±1.50)mmol/L,and the 2 hPG was(6.42±1.18)mmol/L.HbAlc was(7.01±1.40)%significantly better than the reference group(t=5.823,7.240,4.957,P=0.000,0.000,0.000).3.The SD,CV-FPG and MODD of the study group were(0.85±0.26)mmol/L,(0.16±0.03)and(0.65±0.25)mmol/L,respectively,and the control group was(1.43±0.37)mmol/L,respectively.0.24±0.05),(1.39±0.39)mmol/L,the difference was statistically significant(t=8.410,8.997,10.475;P=0.000,0.000,0.000).Conclusion In the clinical practice of obesity and diabetes,the combination of insulin and liraglutide injection can effectively control the blood glucose level.It has reduced efficacy and can improve the fluctuation of blood glucose,and improve the body quality,etc.,and has a high degree of safety,should be further promoted and applied.